Jakavi 20 mg contains Ruxolitinib, a selective JAK1/JAK2 inhibitor that targets abnormal signaling pathways responsible for uncontrolled blood cell production and inflammation. It is widely used in hematology for managing chronic myeloproliferative diseases.

🔬 Mechanism of Action

Ruxolitinib blocks the Janus kinase (JAK) signaling pathway, which plays a key role in hematopoiesis and immune function. By inhibiting overactive JAK signaling, it:

• Reduces excessive blood cell production
• Decreases inflammatory cytokine activity
• Helps shrink enlarged spleen (splenomegaly)
• Improves disease-related symptoms such as fatigue, night sweats, and bone pain

💊 Indications

Jakavi 20 mg is indicated for:

• Primary Myelofibrosis (PMF)
• Post-Polycythemia Vera Myelofibrosis (PPV-MF)
• Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
• Polycythemia Vera (PV) in patients resistant or intolerant to hydroxyurea
• Acute or Chronic Graft-versus-Host Disease (GVHD) (as per approved guidelines)

📌 Key Features of Jakavi 20 mg

• Strength: 20 mg
• Dosage Form: Oral tablet
• Therapeutic Class: JAK1/JAK2 Inhibitor
• Administration: Taken orally, dose adjusted based on platelet count and condition
• Monitoring: Regular complete blood counts (CBC) and liver function monitoring required

⚕️ Benefits of Ruxolitinib

• Effective symptom relief in myelofibrosis
• Reduces spleen enlargement
• Improves overall survival in certain patient groups
• Oral therapy for convenient dosing

⚠️ Precautions

• Risk of anemia and thrombocytopenia
• Increased susceptibility to infections
• Dose adjustments may be required based on blood counts
• Use strictly under hematologist supervision

Jakavi 20 mg (Ruxolitinib Tablets) provides a targeted treatment approach for myeloproliferative disorders and GVHD, helping manage symptoms, control disease progression, and improve patient outcomes under expert medical care.